Overview
Conception.bio creates fertility treatments by turning a person’s blood cells into mature egg cells using induced pluripotent stem cell (iPSC) technology. The process starts with a blood draw, reprogramming cells into iPSCs, and guiding them to become eggs that can be used for reproduction, with optional genetic screening of embryos. The company differentiates itself by offering patient-derived eggs and selling directly to consumers, enabling fertility options outside traditional clinics and appealing to women seeking to extend fertility, infertile couples, and same-sex couples. Its goal is to broaden access to fertility by providing a patient-derived egg platform and direct-to-consumer services, helping people have biological children later in life.
Work here?Claim your company
Simplify's take
What believers are saying
- Conception was still hiring in November 2026, including senior RNA delivery roles.
- Job postings and site updates signal active labs and continued capital support.
- The June 2026 milestone strengthened credibility with investors and fertility-science talent.
What critics are saying
- Clinical use remains years away; Conception still lacks mature antral eggs.
- Safety validation and animal studies remain mandatory before human trials, delaying revenue.
- Ethical backlash and FDA scrutiny can stall funding, partnerships, or the entire company.
What makes Conception unique
- June 2026, Conception announced first early human eggs from stem cells.
- It combines iPSC biology, ovarian organoids, and computational developmental control in Berkeley.
- The platform targets late-age fertility, infertility, and same-sex male biological parenthood.
Help us improve and share your feedback! Did you find this helpful?